A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment

Dementia and Geriatric Cognitive Disorders

Volumn 35, Issue 5-6, 2013, Pages 325-339

  Morimoto, Bruce H ^a   Schmechel, Don ^b   Hirman, Joe ^c   Blackwell, Andrew ^d   Keith, Julian ^e   Gold, Michael ^a   Schmechel, Donald ^f   Kirby, Louis ^f   Huszar, Leslie ^f   Walling, David ^f   Pai, Kamalesh ^f   Huffman, Cynthia ^f   Harper, Linda ^f   McGill, Lora ^f   Stedman, Mary ^f   Vatakis, Nicholas ^f   Winston, Jaron ^f   Gerard, Gary ^f   Ross, Jeffrey ^f   Ross, Joel ^f   Mohammed Bari, ^f   Farmer, Mildred ^f   Thein, Steven ^f   more..

^a Allon Therapeutics Inc   (Canada)

^b Southeastern Neurology and Memory Clinic   (United States)

^c PNW Statistics Inc   (United States)

^d CAMBRIDGE COGNITION   (United Kingdom)

^e UNIVERSITY OF NORTH CAROLINA WILMINGTON   (United States)

^f NONE

Author keywords

Davunetide; Dementia; Drug candidate AL 108; Intranasal dosing; Mild cognitive impairment; Neuroprotection

Indexed keywords

DAVUNETIDE; PLACEBO;

ACUTE PSYCHOSIS; ADULT; AGED; ARTICLE; ATTENTION; BREAST TUMOR; CARDIOMYOPATHY; CASE CONTROL STUDY; COGNITION; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENAL ULCER BLEEDING; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL TASK; MILD COGNITIVE IMPAIRMENT; MUSCULOSKELETAL PAIN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RHINORRHEA; SINGLE DRUG DOSE; SPATIAL MEMORY; STREPTOCOCCUS PNEUMONIA; TREATMENT DURATION; URINARY TRACT INFECTION; WORKING MEMORY; LIQUID CHROMATOGRAPHY; MEDICATION COMPLIANCE; MEMORY; NOSE DISEASE; SIDE EFFECT; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; AGED; AGED, 80 AND OVER; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; OLIGOPEPTIDES; PAIRED-ASSOCIATE LEARNING; PATIENT COMPLIANCE; SPACE PERCEPTION;

EID: 84878127734     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000348347     Document Type: Article

References (36)

1. Gozes I, Brenneman DE: Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J Mol Neurosci 1996; 7: 235-244
2. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, et al: NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 2005; 11: 353-368
3. Gozes I, Bassan M, Zamostiano R, Pinhasov A, Davidson A, Giladi E, et al: A novel signaling molecule for neuropeptide action: Activity-dependent neuroprotective protein. Ann NY Acad Sci 1999; 897: 125-135
4. Zemlyak I, Sapolsky R, Gozes I: NAP protects against cyanide-related microtubule destruction. J Neural Trans 2009; 116: 1411-1416
5. Gozes I, Divinski I, Piltzer I: NAP and D-SAL: Neuroprotection against the beta amyloid peptide (1-42). BMC Neurosci 2008; 9(suppl 3):S3
6. Zaltzman R, Alexandrovich A, Trembovler V, Shohami E, Gozes I: The influence of the peptide NAP on Mac-1-deficient mice following closed head injury. Peptides 2005; 26: 1520-1527
7. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, et al: A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008; 325: 146-153
8. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, et al: Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 2007; 31: 165-170
9. Dubois B: 'Prodromal Alzheimer's disease': A more useful concept than mild cognitive impairment? Curr Opin Neurol 2000; 13: 367-369
10. Morris JC, Price AL: Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001; 17: 101-118
11. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al: Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-1992
12. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999; 56: 303-308
13. Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, et al: Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology 2010; 75: 889-897
14. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al: Mild cognitive impairment. Lancet 2006; 367: 1262-1270
15. Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B: Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord 2006; 22: 312-319
16. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, et al: Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006; 63: 674-681
17. Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, et al: Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006; 63: 665-672
18. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al: Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA 2010; 304: 1903-1911
19. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al: Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA 2009; 302: 2557-2564
20. Saumier D, Aisen PS, Gauthier S, Vellas B, Ferris SH, Duong A, et al: Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: The ALZHEMED (tramiprosate) experience. J Nutr Health Aging 2009; 13: 370-372
21. Gomez-Isla T, Blesa R, Boada M, Clarimon J, Del Ser T, Domenech G, et al: A randomized, double-blind, placebo controlled-Trial of triflusal in mild cognitive impairment: The TRIMCI study. Alzheimer Dis Assoc Disord 2008; 22: 21-29
22. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al: Ginkgo biloba for prevention of dementia: A randomized controlled trial. JAMA 2008; 300: 2253-2262
23. Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, et al: Rofecoxib in patients with mild cognitive impairment: Further analyses of data from a randomized, double-blind trial. Curr Alzheimer Res 2008; 5: 73-82
24. Raschetti R, Albanese E, Vanacore N, Maggini M: Cholinesterase inhibitors in mild cognitive impairment: A systematic review of randomised trials. PLoS Med 2007; 4:e338
25. Zemlyak I, Manley N, Vulih-Shultzman I, Cutler AB, Graber K, Sapolsky RM, et al: The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. J Neurochem 2009; 111: 1252-1263
26. Gozes I, Divinski I: NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res 2007; 4: 507-509
27. Sari Y: Activity-dependent neuroprotective protein-derived peptide, NAP, preventing alcohol-induced apoptosis in fetal brain of C57BL/6 mouse. Neuroscience 2009; 158: 1426-1435
28. AM H: Wechsler Memory Scale III. Arch Clin Neuropsychol 1999; 14: 4
29. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
30. Radloff LS: The CES-D Scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 16
31. Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, et al: NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009; 34: 381-388
32. Collie A, Maruff P: The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment. Neurosci Biobehav Rev 2000; 24: 365-374
33. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al: Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004; 61: 59-66
34. Swainson R, Hodges JR, Galton CJ, Semple J, Michael A, Dunn BD, et al: Early detection and differential diagnosis of Alzheimer's disease and depression with neuropsychological tasks. Dement Geriatr Cogn Disord 2001; 12: 265-280
35. Dudas RB, Clague F, Thompson SA, Graham KS, Hodges JR: Episodic and semantic memory in mild cognitive impairment. Neuropsychologia 2005; 43: 1266-1276
36. Amieva H, Letenneur L, Dartigues JF, Rouch-Leroyer I, Sourgen C, D'Alchee-Biree F, et al: Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord 2004; 18: 87-93